Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome
Information source: University of Colorado
Information obtained from ClinicalTrials.gov on May 09, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Metabolic Syndrome; Insulin Resistance
Intervention: Rosiglitazone (Drug)
Phase: Phase 4
Status: No longer recruiting
Sponsored by: University of Colorado Official(s) and/or principal investigator(s):
Christina L Aquilante, PharmD, Principal Investigator, Affiliation: University of Colorado
Summary
The metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. The purpose of this study is to find out if the medication, rosiglitazone, influences levels of fat cell proteins and alters insulin resistance in nondiabetic persons with the metabolic syndrome. This is an early step to see if a medication, such as rosiglitazone, will be beneficial in people who have the metabolic syndrome.
Clinical Details
Official title:
The Effect of Rosiglitazone on Adipocyte-Derived Cytokines in Nondiabetics With the Metabolic Syndrome
Study design: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 30 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Nondiabetic subjects with an NCEP/ATP III diagnosis of the metabolic syndrome
Exclusion Criteria:
- Statin Medications, liver disease, cardiovascular disease, heart failure, diabetes, chronic kidney disease,
Locations and Contacts
University of Colorado at Denver and Health Sciences Center General Clinical Research Center, Denver, Colorado 80262, United States
Additional Information
Last updated: October 4, 2006
|
